Phase II proof-of-concept trial of ALS 2200 [VLX 135] in combination with GSK 2336805 in treatment-naive patients with chronic, genotype 1 hepatitis C.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2013
Price : $35 *
At a glance
- Drugs JNJ 56914845 (Primary) ; VX 135 (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Jul 2013 Status changed from planning to discontinued, as reported by a Vertex media release.
- 06 Jan 2013 Planned initiation date changed from 1 Mar 2013 to 1 Jun 2013, according to a Vertex Pharmaceuticals media release.
- 06 Jan 2013 Data is expected in the second half of 2013, according to a Vertex Pharmaceuticals media release.